Role of Tigecycline in Treating Bone Infections
Pharmacokinetic Properties and Bone Penetration
- Tigecycline is a broad-spectrum glycylcycline antibiotic that can potentially reach high tissue concentrations in various sites, including bone, with concentrations in lung tissue 2 times higher than serum levels 1, 2
- Tigecycline can penetrate bone tissue effectively, achieving high tissue concentrations, particularly against multidrug-resistant organisms 2, 3
Clinical Applications in Multidrug-Resistant Infections
- Tigecycline is particularly valuable for treating infections caused by carbapenem-resistant gram-negative bacilli (CRAB) and carbapenem-resistant Enterobacteriaceae (CRE) 1, 2
- It has favorable in vitro activity against anaerobic organisms, enterococci, several ESBL-producing organisms, and some strains of carbapenemase-producing Enterobacteriaceae 4, 5
- Tigecycline can be considered as part of combination therapy for multidrug-resistant infections, often combined with carbapenems, sulbactam, aminoglycosides, rifampicin, minocycline, doxycycline, or fosfomycin 1, 2
Limitations and Considerations
- Tigecycline performs poorly in bacteremic patients due to low plasma concentrations, with a higher risk of failing to clear bacteremia 4, 5
- The clinical efficacy of tigecycline is associated with its MIC value against MDR organisms - comparable to polymyxin when MIC ≤2 mg/L, but inferior when MIC >2 mg/L 2, 3
- Adverse effects include nausea, vomiting (6.3%), abdominal pain (18.8%), and potential thrombocytopenia and elevated liver enzymes 2, 3